Sequence: AGYLLGK(Stearyl-rYaOF-eN)LLOOLAAAALOOLL-NH2
| Experiment Id | EXP000951 |
|---|---|
| Paper | Intracellular delivery of therapeutic antisense oligonucleotides targeting mRNA coding mitochondrial |
| Peptide | mitFect7 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 0.3–1.0 µM (depends on MR; oligo 100 nM) |
| Rna Concentration | 100 nM |
| Mixing Ratio | MR 3:1, 7:1, 10:1 (peptide:ASO) |
| Formulation Format | non-covalent peptide/oligonucleotide nanocomplex |
| Formulation Components | Peptide + oligonucleotide in MilliQ water (10% final volume), incubated 1 h RT; added to cells in complete medium |
| Size Nm | 115.80 |
| Zeta Mv | 20.80 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa pLuc705 |
| Animal Model | |
| Administration Route | |
| Output Type | mitochondrial membrane potential (TMRE) + ROS (MitoSOX) |
| Output Value | TMRE uptake increased (6 h & 24 h); ROS increased after 24 h (varies by peptide/MR) |
| Output Units | |
| Output Notes | Functional mitochondrial readouts (TMRE, MitoSOX) used as proxy for UCP2 antisense activity. |
| Toxicity Notes | WST-1: >80% cell viability (tested MRs) |
| Curation Notes |